7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
6 citations
,
May 2018 in “Zeitschrift für Rheumatologie” A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
4 citations
,
May 2020 in “Journal of the American Academy of Dermatology” HS patients rarely see dermatologists, often get opiates, and need better care.
3 citations
,
March 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.
2 citations
,
April 2024 in “Journal of International Medical Research” Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
2 citations
,
January 2016 in “Experimental Dermatology” HS needs personalized treatment plans and more research.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Testosterone therapy significantly improved Hidradenitis Suppurativa symptoms.
1 citations
,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
1 citations
,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
April 2026 in “Journal of Cutaneous Pathology” Alopecia can be caused by multicentric reticulohistiocytosis.
February 2026 in “Cureus” Ciclosporin can cause excessive hair growth even with testosterone blockers.
September 2025 in “International Journal of Innovative Technologies in Social Science” Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
September 2024 in “Dokumentenrepositorium der RUB (Ruhr University Bochum)” Higher monocyte counts predict less effective adalimumab treatment in hidradenitis suppurativa patients.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
August 2024 in “Polo del Conocimiento” Scalp psoriasis is treated with topical therapies, phototherapy, and systemic medications.
July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.
Hidradenitis Suppurativa has genetic links, with certain gene mutations more common in patients and a third of cases having a family history.